Nuvation Bio is a global oncology company whose lead asset, IBTROZI (taletrectinib), is an approved next-generation ROS1 inhibitor for ROS1-positive non-small cell lung cancer. Analysts overwhelmingly rate the stock a Buy, but their price targets are unusually dispersed.
Across the current targets reviewed, the range runs from $7 to $21. At the cautious end, UBS carries a Hold rating with a $7 target, reflecting a more conservative view of the commercial trajectory. At the bullish end, RBC Capital's $20 target and a top-of-range $21 forecast assume the IBTROZI franchise and earlier-stage pipeline are meaningfully underappreciated. In between, HC Wainwright ($17), Citi and JonesTrading and B. Riley Securities ($12 each), and Wedbush, Truist, and JPMorgan ($11 each), plus Jefferies and Citizens JMP ($10 each), cluster in the low-to-mid teens. The arithmetic mean of these targets rounds to roughly $13, which is the figure assessed here.
The dispersion of roughly threefold between the lowest and highest targets signals genuine disagreement about how quickly Nuvation Bio can convert clinical success into durable, profitable revenue growth — not a uniform "analyst consensus."
Nuvation Bio shares closed near $4.20 in recent trading, toward the lower end of a 52-week range of roughly $3.98 to $9.75. Reaching the $13 central target would require a gain of about 210%, which is a very large move. Notably, even the highest analyst target would require the stock to more than double from here, and the 52-week high of $9.75 — a prior peak the stock has already retreated from — sits well below the central target.
The path would almost certainly depend on IBTROZI revenue ramping meaningfully, sustained pipeline progress, and a re-rating of the stock's valuation. The company has reported growing quarterly revenue — about $31.7 million in the quarter ended June 30, 2026 — but still posts substantial GAAP net losses, so the shares currently trade without meaningful earnings-based support.
Several verified developments underpin the bullish case. IBTROZI won full U.S. approval in June 2025, and in September 2026 the FDA approved a supplemental application updating the label with a median duration of response of 49.7 months in TKI-naïve patients — the longest reported for an approved ROS1 TKI. The drug is also advancing globally: it was added to China's National Reimbursement Drug List effective January 2026, and partner Eisai has validated marketing applications in Europe and the U.K.
Beyond taletrectinib, the pipeline includes safusidenib, a brain-penetrant IDH1 inhibitor, and an adjuvant Phase 3 program (TRUST-IV) that could eventually broaden the addressable patient population. A convertible notes offering of up to $230 million also strengthens the balance sheet for advancing these programs.
The principal obstacle is execution risk in a competitive, relatively small market. ROS1-positive NSCLC represents only about 2% of non-small cell lung cancer cases, so revenue growth depends on share capture and geographic expansion rather than a massive patient pool. The company remains unprofitable on a GAAP basis, and the earlier-stage pipeline — including the discontinued NUV-1511 program in late 2025 — carries clinical risk.
Valuation compression is another factor: the stock's recent slide toward its 52-week low shows how quickly sentiment can deteriorate even amid positive regulatory news, and a convertible offering introduces potential future dilution.
From a technical standpoint, the stock is trading near its 52-week low of approximately $3.98, which now acts as a key support level. On the upside, the $5 psychological level and, more importantly, the prior 52-week high near $9.75 represent major resistance zones. Because even the most bullish analyst target lies above that prior high, any sustained move toward $13 would require the stock to first reclaim and hold levels it has not sustained in recent months.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary and none should be treated as a precise timetable. Investors should monitor quarterly IBTROZI revenue and prescription trends, updates on the European and U.K. regulatory review, progress on the TRUST-IV adjuvant study and safusidenib development, cash position and any financing, and any analyst target revisions that reflect changing commercial assumptions.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review alone. For investors tracking a volatile, catalyst-driven name like Nuvation Bio, automated signals can serve as one additional input alongside fundamental and analyst research.
The $13 central target for Nuvation Bio reflects the average of a wide $7-to-$21 range of analyst views and implies a roughly 210% move from the current price near $4.20 — a very large gap. The bullish case rests on a growing, globally expanding IBTROZI franchise and an advancing pipeline, while the bearish case centers on a modest addressable market, persistent losses, and valuation pressure. The extreme spread in targets underscores genuine uncertainty, and reaching $13 would require sustained commercial execution well beyond what the market has priced in so far. Investors should treat the figure as a reference point for debate, not a forecast or a guarantee.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NUVB has been loosely correlated with SVRA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVB jumps, then SVRA could also see price increases.
| Ticker / NAME | Correlation To NUVB | 1D Price Change % | ||
|---|---|---|---|---|
| NUVB | 100% | -3.45% | ||
| SVRA - NUVB | 44% Loosely correlated | -2.57% | ||
| LXEO - NUVB | 44% Loosely correlated | -2.55% | ||
| FDMT - NUVB | 41% Loosely correlated | -0.16% | ||
| VCYT - NUVB | 40% Loosely correlated | -7.18% | ||
| KYTX - NUVB | 39% Loosely correlated | -1.74% | ||
More | ||||